Status:
UNKNOWN
Evaluating PVI Using CMR
Lead Sponsor:
Amsterdam UMC, location VUmc
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Using state of the art cardiac magnetic resonance imaging techniques, characterization of ablation lesions in the early phase after pulmonary vein isolation ablation in atrial fibrillation patients, a...
Eligibility Criteria
Inclusion
- Adult patients (age ≥18 years old)
- Paroxysmal or persistent AF meeting guideline criteria.
- Anticipated PVI using index-guided radiofrequency ablation techniques.
- Availability of LGE-CMR images within 3 months before anticipated PVI.
Exclusion
- History of catheter ablation
- History of cardiac surgery.
- History of chest radiation therapy
- Estimated glomerular filtration rate (eGFR) \<45 ml/min/kg
- Known (or suspected) allergic reaction to gadolinium
- Contraindications for CMR (such as claustrophobia, certain implants, devices, high body mass index).
- Inability to schedule CMR \<48h after PVI
- Long-term use of anti-inflammatory medication, except for the use of nonsteroidal anti-inflammatory drugs
- Autoimmune disease or chronic inflammatory illness.
- Pregnancy of breast feeding
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05437549
Start Date
July 1 2022
End Date
July 1 2024
Last Update
June 29 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.